Combining Iressa and Rapamycin to Treat Kidney Cancer
Author Information
Author(s): Gemmill R M, Zhou M, Costa L, Korch C, Bukowski R M, Drabkin H A
Primary Institution: University of Colorado at Denver and Health Sciences and Cancer Centers
Hypothesis
The combination of an EGFR inhibitor plus rapamycin might inhibit growth in RCC cell lines in a synergistic manner.
Conclusion
The study found that combined inhibition of EGFR and mTOR provides a more effective growth blockade in RCC cell lines than either agent alone, particularly in cells with wild-type VHL.
Supporting Evidence
- Combined EGFR and mTOR inhibition was more effective in RCC cell lines with wild-type VHL.
- Phosphorylation of ERK1/2 and RPS6 was selectively inhibited in cells with wild-type VHL.
- Most RCC tumors expressed more EGFR protein than normal kidney tissue.
Takeaway
Researchers found that using two drugs together can help stop kidney cancer cells from growing better than using just one drug.
Methodology
The study used RCC cell lines and patient tumors to analyze the effects of Iressa and rapamycin on cell growth and signaling pathways.
Potential Biases
Potential bias may arise from the selection of cell lines and the specific conditions under which experiments were conducted.
Limitations
The study's findings may not be generalizable to all RCC patients due to the limited number of cell lines and tumors analyzed.
Participant Demographics
The study involved 12 renal cell carcinoma tumors from patients, but specific demographic details were not provided.
Statistical Information
P-Value
0.08
Statistical Significance
p=0.08
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website